Unknown

Dataset Information

0

Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.


ABSTRACT: The aryl hydrocarbon receptor (AHR) was initially identified as a receptor that bound 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related environmental toxicants; however, there is increasing evidence that the AHR is an important new drug target for treating multiple diseases including breast cancer. Treatment of estrogen receptor (ER)-negative MDA-MB-231 and BT474 breast cancer cells with TCDD or the selective AHR modulator 6-methyl-1,3,-trichlorodibenzofuran (MCDF) inhibited breast cancer cell invasion in a Boyden chamber assay. These results were similar to those previously reported for the antimetastic microRNA-335 (miR-335). Both TCDD and MCDF induced miR-335 in MDA-MB-231 and BT474 cells and this was accompanied by downregulation of SOX4, a miR-335-regulated (inhibited) gene. The effects of TCDD and MCDF on miR-335 and SOX4 expression and interactions of miR-335 with the 3'-UTR target sequence in the SOX4 gene were all inhibited in cells transfected with an oligonucleotide (iAHR) that knocks down the AHR, thus confirming AHR-miR-335 interactions. MCDF (40 mg/kg/d) also inhibited lung metastasis of MDA-MB-231 cells in a tail vein injection model, showing that the AHR is a potential new target for treating patients with ER-negative breast cancer, a disease where treatment options and their effectiveness are limited.

SUBMITTER: Zhang S 

PROVIDER: S-EPMC3256275 | biostudies-other | 2012 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.

Zhang Shu S   Kim KyoungHyun K   Jin Un Ho UH   Pfent Catherine C   Cao Huojun H   Amendt Brad B   Liu Xinyi X   Wilson-Robles Heather H   Safe Stephen S  

Molecular cancer therapeutics 20111027 1


The aryl hydrocarbon receptor (AHR) was initially identified as a receptor that bound 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related environmental toxicants; however, there is increasing evidence that the AHR is an important new drug target for treating multiple diseases including breast cancer. Treatment of estrogen receptor (ER)-negative MDA-MB-231 and BT474 breast cancer cells with TCDD or the selective AHR modulator 6-methyl-1,3,-trichlorodibenzofuran (MCDF) inhibited breast cancer c  ...[more]

Similar Datasets

| S-EPMC5698877 | biostudies-literature
| S-EPMC5853108 | biostudies-literature
| S-EPMC5862868 | biostudies-literature
| S-EPMC7916741 | biostudies-literature
| S-EPMC2802893 | biostudies-literature
| S-EPMC5459550 | biostudies-literature
| S-EPMC5941192 | biostudies-literature
| S-EPMC4303521 | biostudies-literature
| S-EPMC7007633 | biostudies-literature
| S-EPMC4130779 | biostudies-literature